The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

The primary objective is to differentiate the clinical utility of Prospera testing from the use of creatinine testing as measured by the proportion of positive biopsies in post renal allograft patients. Secondary objectives include: * To observe the performance of the Prospera assay in detecting AR (repeated validation) * To evaluate whether Prospera can detect AR earlier and more often than SCr * To determine whether use of Prospera will significant decrease the rate of overall number of biopsies when compared to the rate of biopsies in the control arm